论文部分内容阅读
作者采取随机双盲对照试验,选择10例正常男性和8例(男、女各4例)哮喘患者.早晨测定基础肺功能,然后口服安慰剂或氯压定,健康者200μg,哮喘患者150μg,每30min 测量1次心率和动脉压,2h 后测定FRC、VC,FEV_1,建立剂量反应曲线。再给予组胺雾化剂,首剂健康者3.5μmol,哮喘者1.1μmol,以后每5min 给予1次加倍剂量的组胺,共1～4次,使FEV_1下降>15%。结果氯压定对正常人和哮喘患者FEV1没有影响;健康者安慰剂组和氯压定组用组胺前后的FEV1无差别。而哮喘者使用大剂量组胺后氯压定组FEV1的下降显著大于安慰剂组(p<0.001),氯压定对心血管的影响为血压进行性下降(p<0.001),心率
In a randomized, double-blind, controlled trial, 10 normal men and 8 asthma patients (4 males and 4 females) were enrolled in this study, with baseline lung function measured in the morning and placebo or clonidine orally, 200 μg healthy, 150 μg asthma, The heart rate and arterial pressure were measured every 30 minutes. FRC, VC and FEV_1 were measured after 2 hours and the dose response curve was established. And then given histamine nebulizer, the first dose of 3.5μmol healthy, asthma 1.1μmol, after every 5min to give a double dose of histamine, a total of 1 to 4 times, so that FEV_1 decreased by> 15%. Results Clonazepam had no effect on FEV1 in normal subjects and asthma patients. There was no difference in FEV1 before and after histamine administration in both placebo and clonidine groups. The decrease in FEV1 was significantly greater in the clindaminated clonidine group than in the placebo group (p <0.001). The effects of clonidine on cardiovascular outcomes were decreased (p <0.001), heart rate